Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9-11, 12-14 or 15-17 months of age.
Children aged 9-11, 12-14 or 15-17 months, respectively were vaccinated with a measles, mumps and rubella (MMR) vaccine and serum antibody responses and reactogenicity were compared. The data of 118 children could be analysed (group 1=9-11 months, n=46; group 2=12-14 months, n=29, group 3, 15-17 months, n=43). The only significant difference observed was for seroconversion against measles virus between group 1 and group 3 (84.8% vs 100%, p=0.012). No serious adverse events were reported. Local side reactions were mild, infrequent and independent of age. Immunisation against MMR is safe and effective even when administered before the currently recommended age of 12 months.
Klinge
J
J
Hospital for Children and Adolescents, University of Erlangen-Nuremberg, Germany.
Lugauer
S
S
Korn
K
K
Heininger
U
U
Stehr
K
K
D000367:Age Factors; D000914:Antibodies, Viral / Q000097:blood*; D005334:Fever / Q000209:etiology; D006801:Humans; D007223:Infant; D008458:Measles Vaccine / Q000009:adverse effects / Q000276:immunology*; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine / Q000009:adverse effects / Q000276:immunology*; D012411:Rubella Vaccine / Q000009:adverse effects / Q000276:immunology*; D014611:Vaccination; D017778:Vaccines, Combined / Q000009:adverse effects / Q000276:immunology
D000914:Antibodies, Viral; D008458:Measles Vaccine; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine; D012411:Rubella Vaccine; D017778:Vaccines, Combined